212 related articles for article (PubMed ID: 36409491)
1. Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Gaba P; Bhatt DL; Dagenais GR; Bosch J; Maggioni AP; Widimsky P; Leong D; Fox KAA; Yusuf S; Eikelboom JW;
JAMA Netw Open; 2022 Nov; 5(11):e2243201. PubMed ID: 36409491
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.
Farrant M; Easton JD; Adelman EE; Cucchiara BL; Barsan WG; Tillman HJ; Elm JJ; Kim AS; Lindblad AS; Palesch YY; Zhao W; Pauls K; Walsh KB; Martí-Fàbregas J; Bernstein RA; Johnston SC
JAMA Netw Open; 2019 Sep; 2(9):e1910769. PubMed ID: 31490536
[TBL] [Abstract][Full Text] [Related]
3. Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.
Perera KS; Ng KKH; Nayar S; Catanese L; Dyal L; Sharma M; Connolly SJ; Yusuf S; Bosch J; Eikelboom JW; Hart RG
JAMA Neurol; 2020 Jan; 77(1):43-48. PubMed ID: 31524941
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
Lamy A; Eikelboom J; Sheth T; Connolly S; Bosch J; Fox KAA; Zhu J; Lonn E; Dagenais G; Widimsky P; Branch KRH; Bhatt DL; Zheng Z; Straka Z; Dagenais F; Kong Y; Marsden T; Lee SF; Copland I; Yusuf S
J Am Coll Cardiol; 2019 Jan; 73(2):121-130. PubMed ID: 30654882
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Eikelboom JW; Connolly SJ; Bosch J; Dagenais GR; Hart RG; Shestakovska O; Diaz R; Alings M; Lonn EM; Anand SS; Widimsky P; Hori M; Avezum A; Piegas LS; Branch KRH; Probstfield J; Bhatt DL; Zhu J; Liang Y; Maggioni AP; Lopez-Jaramillo P; O'Donnell M; Kakkar AK; Fox KAA; Parkhomenko AN; Ertl G; Störk S; Keltai M; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Verhamme PB; Vinereanu D; Kim JH; Tonkin AM; Lewis BS; Felix C; Yusoff K; Steg PG; Metsarinne KP; Cook Bruns N; Misselwitz F; Chen E; Leong D; Yusuf S;
N Engl J Med; 2017 Oct; 377(14):1319-1330. PubMed ID: 28844192
[TBL] [Abstract][Full Text] [Related]
8. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
Bhatt DL; Eikelboom JW; Connolly SJ; Steg PG; Anand SS; Verma S; Branch KRH; Probstfield J; Bosch J; Shestakovska O; Szarek M; Maggioni AP; Widimský P; Avezum A; Diaz R; Lewis BS; Berkowitz SD; Fox KAA; Ryden L; Yusuf S;
Circulation; 2020 Jun; 141(23):1841-1854. PubMed ID: 32223318
[TBL] [Abstract][Full Text] [Related]
9. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease.
Steffel J; Eikelboom JW; Anand SS; Shestakovska O; Yusuf S; Fox KAA
Circulation; 2020 Jul; 142(1):40-48. PubMed ID: 32436455
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
Zheng N; Zhong J; Chen X; Su J; Liu C; Jiang L
Am J Cardiovasc Drugs; 2023 May; 23(3):257-267. PubMed ID: 36867384
[TBL] [Abstract][Full Text] [Related]
11. A hybrid automated event adjudication system for clinical trials.
Yuan F; Bosch J; Eikelboom J; Dagenais GR; Connolly S; Belanger J; Marsden T; Tang C; Swaminathan B; Renters M; Dyal L; Bangdiwala SI
Clin Trials; 2023 Apr; 20(2):166-175. PubMed ID: 36734212
[TBL] [Abstract][Full Text] [Related]
12. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
Gaba P; Bhatt DL; Giugliano RP; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Ballantyne CM; Pinto DS; Budoff MJ; Gibson CM
J Am Coll Cardiol; 2021 Oct; 78(15):1525-1537. PubMed ID: 34620410
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Sharma M; Hart RG; Smith EE; Bosch J; Eikelboom JW; Connolly SJ; Dyal L; Reeh KW; Casanova A; Diaz R; Lopez-Jaramillo P; Ertl G; Störk S; Dagenais GR; Lonn EM; Ryden L; Tonkin AM; Varigos JD; Bhatt DL; Branch KRH; Probstfield JL; Kim JH; O'Donnell M; Vinereanu D; A A Fox K; Liang Y; Liu L; Zhu J; Pogosova N; Maggioni AP; Avezum A; Piegas LS; Keltai K; Keltai M; Berkowitz SD; Yusuf S
Stroke; 2020 Oct; 51(10):2901-2909. PubMed ID: 32951537
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
Fox KAA; Eikelboom JW; Shestakovska O; Connolly SJ; Metsarinne KP; Yusuf S
J Am Coll Cardiol; 2019 May; 73(18):2243-2250. PubMed ID: 31072566
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial.
Harper C; Mafham M; Herrington W; Staplin N; Stevens W; Wallendszus K; Haynes R; Landray MJ; Parish S; Bowman L; Armitage J
JAMA Netw Open; 2021 Dec; 4(12):e2139748. PubMed ID: 34962561
[TBL] [Abstract][Full Text] [Related]
17. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
[TBL] [Abstract][Full Text] [Related]
18. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
19. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
Debus ES; Nehler MR; Govsyeyev N; Bauersachs RM; Anand SS; Patel MR; Fanelli F; Capell WH; Brackin T; Hinterreiter F; Krievins D; Nault P; Piffaretti G; Svetlikov A; Jaeger N; Hess CN; Sillesen HH; Conte M; Mills J; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP
Circulation; 2021 Oct; 144(14):1104-1116. PubMed ID: 34380322
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
Guzik TJ; Ramasundarahettige C; Pogosova N; Lopez-Jaramillo P; Dyal L; Berkowitz SD; Muehlhofer E; Bhatt DL; Fox KAA; Yusuf S; Eikelboom JW
J Am Coll Cardiol; 2021 Feb; 77(5):511-525. PubMed ID: 33538248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
